ArticleEuropean radiology2026
Auto-LSN: fully automated liver surface nodularity quantification in CT based on deep learning for the evaluation of advanced chronic liver disease.
Article in European radiology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
objectivesLiver surface nodularity (LSN) is a recognized non-invasive biomarker of cirrhosis. This study introduces auto-LSN, an artificial intelligence (AI)-based algorithm for fully automated LSN quantification, assesses its association with fibrosis stage and its non-inferiority in diagnostic performance for advanced chronic liver disease (ACLD) and cirrhosis compared to the FDA-approved, semi-automated liver boundary analysis (LBA) software. MATERIALS AND
methodsThis retrospective, bicentric study included patients with chronic liver disease risk factors who underwent CT and liver biopsy between April 2014 and March 2020. Fibrosis stages were grouped into F3-F4 (ACLD) vs F0-F2, and F4 (cirrhosis) vs F0-F3 per the METAVIR. LSN was measured with auto-LSN and LBA. Their association with fibrosis grade and diagnostic accuracy for ACLD and cirrhosis were compared using a -0.05 non-inferiority margin. Mann-Whitney-Wilcoxon tests, Spearman correlation, and area under the receiver operating characteristic curve (AUC) were used.
resultsIn 127 patients (68 ± 12 years; 97 men), auto-LSN demonstrated a positive correlation with fibrosis stage (ρ = 0.59; 95% CI [0.48, 0.68]), similar to LBA (ρ = 0.44; 95% CI [0.32, 0.55]), both p < 0.001, with differences within the non-inferiority margin ([0.03, 0.26]). Auto-LSN achieved AUCs of 0.79 (95% CI [0.70, 0.87]) for ACLD and 0.84 (95% CI [0.76, 0.91]) for cirrhosis, comparable to LBA's AUCs of 0.73 (95% CI [0.64, 0.82]) and 0.74 (95% CI [0.66, 0.83]), respectively. All differences were within the non-inferiority margin.
conclusionAuto-LSN correlates positively with fibrosis stage and provides non-inferior diagnostic performance compared to LBA. Its full automation and accuracy support its potential for opportunistic screening and objective patient monitoring. KEY POINTS: Question LSN is a key radiological feature for non-invasive ACLD diagnosis. However, current LSN quantification software is only semi-automated, thus time-consuming. Findings The fully automated auto-LSN algorithm for LSN quantification achieved statistically non-inferior diagnostic performance compared to existing semi-automated software for the detection of ACLD and cirrhosis. Clinical relevance Auto-LSN, as a fully automated solution, offers a reliable alternative to existing semi-automated software, enabling mass opportunistic screening of the general population-by evaluating all CT scans performed for any indication-and supporting objective follow-up of at-risk patients.
Indexed as
Identifiers
41642300What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.